Monthly Archives: May 2010

Blockbuster Drugs — Alive and Well

Jacky Law says that news of the blockbuster’s death has been greatly exaggerated. But it may no longer be the preserve of Big Pharma. There was a time not so long ago when people would pay good money to find out where the industry was at, let alone where it was going. Now, thanks to […]
Posted in Strategy | Leave a comment

Abbott Shells Out $3.7 Billion for Piramal

In July 2009, judging solely by total revenue, Abbott was assigned the rank of the eighth-largest pharmaceutical company in the Fortune Global 500. Nearly a year later, the company is looking to move up at least a few notches. On May 21, Abbott acquired Indian generic giant Piramal for a cool $2.12 billion up front, […]
Posted in Strategy | Tagged , , , , , , , , , | Leave a comment

WHO Threatens Industry Shut-out on Counterfeit Regulation

Big Pharma believes that a global generics franchise might give it a softer landing off the patent cliff, but governments that sponsor and regulate the industry are still acting a bit slow on the uptake. The reason? Anti-IP activists are again poisoning the well on global access to medicines, engaging the bigger emerging market governments […]
Posted in Global | Tagged , , , , , , | Leave a comment

Pharma Digital Smarts Quantified in IQ Index

Pfizer’s Viagra and AstraZeneca’s (AZ) Nexium took the top two slots on a new Digital IQ Index measuring the digital competence of 51 pharma brands across eight therapeutic categories. The ranking, created by think tank L2 in partnership with media agency PHD Network, evaluated brands’ digital presence across four criteria: platform (including site effectiveness and […]
Posted in E-Media | Tagged , , , , , , , , , | 1 Comment

Post-Approval Regulatory Priorities: Progress or Pile-Up?

An enduring falsehood about the pharmaceutical industry is that the heavy lifting ends with a successful new drug registration. What comes after is the equivalent of a well-funded retirement, where providers embrace the therapy, payers meet the price, and patients push the boundaries of clinical practice toward lucrative new indications. The reality, however, is starkly […]
Posted in Regulatory | Tagged , , , , , | 2 Comments
  • Categories

  • Meta